Crossmark

Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer

Crossref DOI link: https://doi.org/10.1007/s12609-018-0296-5

Published Online: 2018-11-06

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Roussos Torres, Evanthia T.

Connolly, Roisin M.
License Information

Text and Data Mining valid from 2018-11-06
More Information

Article History

First Online: 6 November 2018

Compliance with Ethical Standards

:

: Evanthia T. Roussos Torres declares that she has no conflict of interest.Roisin M. Connolly has received research funding (through grants to her institution) from Genentech, Puma Biotechnology, Novartis, Merck, Merrimack Pharmaceuticals, and MacroGenics.

: This article does not contain any studies with human or animal subjects performed by any of the authors.